Abstract

Recently, microRNAs (miRNAs) have emerged as key factors involved in a series of biological processes, ranging from embryogenesis to programmed cell death. Its link to aberrant expression profiles has rendered it a potentially attractive tool for the diagnosis, prognosis, or treatment of various diseases. Accumulating evidence has indicated that miRNAs act as tumor suppressors in hepatocyte malignant transformation by regulating development, differentiation, proliferation, and tumorigenesis. Here, we summarize recent progress in the development of novel biomarker-based miRNA therapeutic strategies for hepatocellular carcinoma (HCC).

Introduction

Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies worldwide. The etiology of HCC is a multi-factorial, multistep, and complex process involving chronic and persistent hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and alcohol and aflatoxin B1 intake. HCC is a highly chemoresistant cancer with no effective systemic or well-established adjuvant therapies, and its prognosis remains poor because of its higher recurrence. Hepatic resection or transplantation is the only potential curative treatment for HCC patients.

MicroRNAs (miRNAs) are small non-coding RNA molecules that function as endogenous transcriptional and post-transcriptional regulators of gene expression by silencing numerous target genes. Hundreds of miRNAs have been identified in the human genome and tumor tissues. Comprehensive studies of the altered expression of cancer-related miRNAs have allowed for a better understanding of HCC tumor growth, metastatic potential, and recurrence. Recently, RNA interference (RNAi) has emerged as an innovative gene silencing technology strategy for the treatment of HCC and other tumors.

Extensive studies of miRNA function have uncovered its role in many biological activities, ranging from embryonic development to cell death. Compelling evidence has revealed that miRNA is an important player in the modulation of diverse cellular processes by targeting coding genes or long non-coding RNAs. The discovery that more than a 1000 miRNAs are encoded in the human genome further extends our understanding of the complexity of gene regulation. A number of miRNAs are highly conserved across a wide range of distinct species, some with suppressing roles in HCC. As such, the innovative use of hepatoma-related miRNAs as either biomarkers of disease progression or tumor suppressors therapeutically is a promising tool for those with HCC. In this review, we summarize the progress of the development of novel biomarker-based miRNA gene therapeutic strategies for HCC.

Targeting hepatoma-related oncogene

The discovery of aberrant miRNA expression profiles in liver cancer largely extended our understanding of HCC, and recent studies have shown that miRNA may be a specific and accurate tool for the clinical diagnosis, prognosis, and treatment of HCC. In order to develop potential therapeutic tools for cancer therapy, researchers utilize viral vector systems to elevate tumor suppressive miRNAs to eliminate carcinogenesis and anti-miRNA oligonucleotides to promote tumorigenesis.

Of the reported approaches for in vivo miRNA delivery, the adenoviral associated viral vector was the most promising for HCC because of the lower risk of vector-related toxicities and higher gene transfer efficacy. The level of miR-26a expression is significantly downregulated in the murine model of MYC-induced hepatoma (tet-o-MYC; LAP-TTA mice), which targets cyclin D2 or E2, two influential players in G1/S cell phase. Ectopic expression of miR-26a inhibited cell proliferation and induced tumor cell apoptosis, suggesting that miRNAs with tumor suppressive function may be useful for the treatment of HCC.
In addition to viral vectors, artificially synthesized miRNA or anti-miRNA oligonucleotides may be an efficacious therapeutic strategy for cancer therapy. MiR-221 is overexpressed in HCC, and the relative expression of miR-221 in clinical TNM stages III and IV was significantly higher than in stages I and II. The effectiveness of anti-miR-221 oligonucleotides varied depending on the different chemical modification forms. Of the nine forms evaluated, a cholesterol-modified isoform of anti-miR-221 significantly impaired cancer cell proliferation both in vitro and in vivo. Transgenic mice that overexpress miR-221 in the liver spontaneously developed liver tumors, and in vivo delivery of antisense 2'-O-methyloligoribonucleotide that targeted miR-221 resulted in prolonged survival and significant reduction of the number of tumor nodules. Therefore, use of oligonucleotides may be an effective critical targeted therapy for HCC.

**Targeting hepatoma-specific protein**

**Osteopontin (OPN)**

Similarly, restoration of some miRNAs that serve as tumor suppressors could significantly block tumorigenesis and metastasis in vivo. It is well characterized that OPN is overexpressed in liver cancer patients with enhanced metastasis and poor prognosis, and repression of OPN using a neutralizing antibody significantly weakened cell migration and invasiveness in vitro. The artificial miRNAs, designated for targeting OPN, significantly inhibited OPN expression in the HCCLM3 cell line and resulted in decreased in vivo tumor growth and lung metastasis through the repression of matrix metalloproteinase 2 and nuclear factor kappa B (NF-κB) pathways.

**Glypican-3 (GPC-3)**

GPC-3 is a membrane anchored heparin sulfate proteoglycan expressed in fetal liver and placenta but not in normal adult liver tissue. It is specifically overexpressed in hepatoma. Silencing the expression of GPC-3 with transfected miRNA was shown to decrease HepG2-linked cell proliferation and inhibit HepG2 mRNA and protein levels. Proliferation was inhibited by 71.1% in the miRNA group and 79.5% in the miRNA plus sorafenib (100 μM/L) group. Transfected cells were arrested in the G1 phase of the cell cycle, and apoptosis rate was increased from 42.2% in the neg-miRNA group to 65.6% in the miRNA group. As shown in Fig. 1, miRNA specific for GPC-3 might inhibit HCC cell proliferation by cell apoptosis in vitro. GPC-3 miRNA mediated downregulation of GPC-3 expression was shown to inhibit xenograft tumor growth in naked mice through the Wnt/β-catenin signaling pathway in vivo. Taken together, these findings identify GPC-3 gene as a potential molecular target for HCC gene therapy.

**Alpha-fetoprotein (AFP)**

To date, circulating AFP is the most commonly used biomarker to screen for HCC. There are two subtypes for prognostic prediction: EpCAM+AFP+ HCC (hepatoma stem cell (HSC)-HCC) with enhanced metastatic properties and poor outcome and EpCAM AFP HCC (mature hepatocyte-like HCC; MH-HCC) with good prognosis. Detection of EpCAM and AFP expression status are performed in conjunction with transcriptome analysis in HCC specimens. When comparing miRNA expression profiles between the two groups, the specific miRNAs preferentially expressed in HSC-HCC and the highly conserved miR-181 families are highly expressed in EpCAM+ AFP+ cells isolated from AFP+ HCC specimens.
Downregulating expression of key molecules in HCC-related pathways

Several signaling pathways have been unraveled in the study of hepatocarcinogenesis, including PI3KCA2/Akt/HIF-1α, NF-κB, insulin-like growth factor (IGF)-II/IGF-IR, met, myc, transforming growth factor (TGF)-β, hedgehog, p53, Wnt/β-catenin, and epidermal growth factor (EGF). Many of these pathways overlap with pathways associated with hepatic progenitor cells.45,46 miRNA and other non-coding RNAs have been reported in HSCs. Based on computational and experimental evidence, it has been estimated that miRNAs encoded by the genome could modulate approximately 60% of mammalian genes, highlighting the importance of miRNAs in the orchestration of gene expression.47 Furthermore, a single miRNA may affect the expression levels of multiple target genes. Therefore, it will not be surprising that a single miRNA would act in both normal into cancer cells to functionally regulate carcinogenesis.48

Wnt/β-Catenin pathway

Abnormal expressions of some key molecules in the Wnt/β-Catenin pathway were associated with the occurrence and development of HCC. The Wnt proteins are secreted glycoproteins that bind to the N-terminal extracellular cysteine-rich domain of the Frizzled (Fzd) receptor family. Activation of Fzd receptors by Wnt activates canonical and non-canonical Wnt pathways.49 The Fzd7, a member of the Fzd family, is commonly upregulated in a variety of cancers, including HCC and triple negative breast cancer and plays an important role in stem cell biology and hepatoma progression. Inhibition of Fzd7 with siRNA knockdown, anti-Fzd7 antibodies, or the extracellular peptide of Fzd7 (soluble Fzd7 peptide) promoted anti-cancer activity in vitro and in vivo mainly by inhibiting the canonical Wnt signaling pathway.49 In addition, pharmacological inhibition of Fzd7 by small interfering peptides or a small molecule inhibitor suppressed β-catenin–dependent tumor cell growth. Therefore, targeted inhibition of Fzd7 represents a rational and promising new approach for cancer therapy.

IGF-II/IGF-IR pathway

IGF-II is a mitogenic polypeptide closely linked to the complex regulation of transcription, and its expression results in generation of multiple miRNAs initiated by different promoters.50,51 Because both IGF-II and IGF-I receptors are highly overexpressed in hepatocarcinogenesis, IGF-II is suspected to serve as an autocrine growth factor.52,53 Downregulation of IGF-II expression by specific miRNAs resulted in viability alteration, proliferation inhibition, and apoptosis in HepG2 cells. The level of vascular endothelial growth factor (VEGF) expression in the supernatant of HepG2 cells in the miRNA-IGF-II transfected group was significantly less and the susceptibility to anoikis and anchorage-indep-endent colony formation decreased than those in the untransfected or the miRNA-neg transfected group.54 In hepatoma cells transfected with IGF-IR-miRNA, cell cycle progression was inhibited through G0/G1 arrest in Bel-7404 and PLC/PRF/5 cells, cell proliferation was inhibited with apoptosis, and the expression of cyclinD1 was significantly inhibited in vitro. In addition, the growth of xenograft tumors was significantly inhibited in vivo (Fig. 2). Taken together, these findings suggest that IGF-II or IGF-IR is a potential molecular target for HCC gene therapy.

NF-κB pathway

Chronic infection with HBV or HCV is involved in the development and progression of HCC. Hepatitis virus with tumorigenic protein (HBx or core protein of HCV) can activate a variety of signaling pathways, including NF-κB, that modulate the expression of many genes linked with HCC. The effects of siRNA-mediated inhibition of NF-κB on cell growth were investigated in hepatoma cells. Prior to transfection, the expression of NF-κB/p65 mRNA was significantly higher in HepG2 cells than that in LO2 cells, whereas the expression levels of NF-κB/p65 mRNA and protein in HepG2 cells were significantly reduced in p65 siRNA transfected cells. Interestingly, the apoptosis index was increased up to 85% in HepG2 cells and overexpression of NF-κB in hepatoma cells can be inhibited by p65 siRNA via an apoptotic mechanism, suggesting that NF-κB may be a viable molecular-target for HCC gene therapy.53

Fig. 2. Alterations of histopathology and immunohistochemistry in xenograft tumors. (A) The size and gross features of xenograft tumors in nude mice from the different treatment groups: control group, PLC/PRF/S cells transfected without any miR; the neg-miR group, PLC/PRF/S cells transfected with neg-miR; the miR group, PLC/PRF/S cells transfected with miR; (B) IGF-IR IGF-IR immunohistochemical analysis of the xenograft tumor tissues (SP, 400 ×) (unpublished data, Yao et al.).

Yao M. et al: Biomarker miR in HCC therapy

It was determined experimentally that the miR-181 family members target Caudal type homeobox transcription factor 2, GATA binding protein 6, and Nemo-like kinase, proteins essential for cell differentiation and the Wnt signaling pathway. The sophisticated molecular alternation in hepatocarcinogenesis provides a long-lasting challenge for researchers, and EpCAM/AFP. HCC patients might be potential therapeutic candidates for anti-angiogenesis therapy.44 Although encouraging progress has been achieved regarding the elucidation of the molecular mechanism of miRNA and HSCs, future studies are needed to further determine how miRNAs are involved in HSC development and tumor progression.
Therapeutic miRNAs and effects on HCC drug-resistance

Aberrently expressed miRNAs have been identified in HCC drug-resistance mechanisms. HCC tissues are organized in a hierarchy consisting of heterogeneous cell populations, and the capability to maintain tumorigenesis exclusively relies on a small population of hepatic stellate cells (HSCs). The aforementioned new findings largely extend our understanding of the regulation of HSCs and shed light on the development of novel therapeutic strategies to fight against chemotherapy-resistant HCC. MiRNA-based therapies that specifically target the regulation of HSCs and shed light on the development of new curative approaches is required. In general, many questions remain and a new perspective regarding the significance for HCC because of the lack of effective systemic therapies for HCC. The transcription and activation of specific vector mediated RNAi has been successfully used to suppress hepatoma cells via viability alteration, proliferation inhibition, and vector mediated RNAi has been successfully used to suppress hepatoma cells. However, technical difficulties, including stability and the bioavailability of RNAi-based therapeutics, have restricted the development of miRNA clinically. Despite the inspiring progress in miRNA-mediated gene activation techniques and insight into the mechanisms of tumorigenesis, many questions remain and a new perspective regarding the development of new curative approaches is required. In general, the use of miRNAs is a promising area for the development of novel therapeutic strategies for HCC.

Conclusions

Increasing evidence has highlighted the importance of miRNAs in the control of HCC suppressors, growth, invasiveness, and curability (Table 1). The management of advanced HCC is entering a new era of molecular targeting therapy, which is of particular significance for HCC because of the lack of effective systemic therapies for HCC. The transcription and activation of specific vector mediated RNAi has been successfully used to suppress hepatoma cells via viability alteration, proliferation inhibition, and promotion of apoptosis. However, technical difficulties, including stability and the bioavailability of safety of miRNAs-based therapies, have restricted the development of miRNA clinically. Despite the inspiring progress in miRNA-mediated gene activation techniques and insight into the mechanisms of tumorigenesis, many questions remain and a new perspective regarding the development of new curative approaches is required. In general, the use of miRNAs is a promising area for the development of novel therapeutic strategies for HCC.

Acknowledgments

This work was partially supported by the Grants from the National Natural Science Foundation (81200634), the Projects of Jiangsu Medical Science (2013-WSW-011, HK201102, BL2012053) & the Qinglan Project of higher education (12KJB310013), and the International S & T Cooperation Program (2013DFA32150) of China. We thank T. FitzGibbon, M.D., for helpful comments on earlier drafts of the manuscript.
Yao M. et al: Biomarker miR in HCC therapy

Conflict of Interest
None

Author contributions
Writing the manuscript and creating figures and table (MY, LW), performing literature searches (YY, HBG), editing and reviewing the manuscript (DPY).

References
[1] Li J, Shi W, Gao Y, Yang B, Jing X, Shan S, et al. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. Clin Lab 2013;59:1009–1015.
[2] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245–1255. doi: 10.1016/S0140-6736(11)6347-0.
[3] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273. doi: 10.1016/j.gastro.2011.12.061.
[4] Yang YH, Wen TF, Chen X. Resection margin in hepatotbectomy for hepatocellular carcinoma: a systematic review. Gastroenterology 2012;59: 1393–1397. doi: 10.1053/j.heg.10690.
[5] Tazielli M, Essadi I, Mrabbi H, Touay A, Errihani PH. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci 2011;3:167–175. doi: 10.4297/najms.2011.3167.
[6] Cao H, Phan H, Yang LX, Touyar A, Errihani PH. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 2012;32:1379–1386.
[7] Hellouo E, Lesurtel M, Carr BJ, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol 2012;39:510–521. doi: 10.1053/j.seminoncol.2012.05.008.
[8] Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 2012;82:275–289. doi: 10.1159/000337293.
[9] Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009;9:503–509. doi: 10.1586/era.09.6.
[10] Broderick JA, Zamore PD. MicroRNA therapeutic. Gene therapy 2011;18: 1104–1110. doi: 10.1038/gt.2011.50.
[11] Yu X, Lee SA, Chen X. RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov 2011;6:106–115. doi: 10.2174/1754892110793980997.
[12] Gailhouste E, Ochiya T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol 2013;28:437–451.
[13] Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in hepatocellular carcinoma. J Transl Med 2010;8:271:760–7616. doi: 10.1159/00035458.
[14] Ronald JA, Katzenberg R, Nielsen CH, Jae HJ, Hofmann LV, Gambhir SS. The next generation therapeutic targets in human diseases. Theranostics 2013;3:943–952. doi: 10.7150/thno.7445.
[15] Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013;58:158–170. doi: 10.1002/hep.26305.
[16] Chen L, Zheng J, Zhang Y, Wang J, Ni J. et al. Target-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther 2011;19: 1521–1528. doi: 10.1038/mt.2011.64.
[17] Huang X, Jia Z. Construction of HCC-targeting artificial miRNAs using natural miRNA precursors. Exp Ther Med 2013;6:209–215. doi: 10.3892/etm.2013.1111.
[18] Dong ZZ, Yao M, Wang L, Gu X, Shi Y, Qiu LW, et al. Epigenetic alterations of hepatitis B-associated-IGF-II gene promoter and IGF-II abnormal expression in HBV-related hepatocellular carcinoma. Biomed Pharmacol J 2013;6:177–187. doi: 10.13005/bpj/401.
[19] Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013;19:7836–7845. doi: 10.3748/wjg.v19.i44.7836.
[20] Chen Z, Ma T, Huang C, Zhang L, Xu T, Hu T, et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene 2014;533:456–457. doi: 10.1016/j.gene.2013.09.067.
[21] Yan H, Wang S, Yu H, Zhu J, Chen C. Molecular pathways and functional analysis of mRNA expression associated with paclitaxel-induced apoptosis in hepatocellular carcinoma cells. Pharmacology 2013;92:167–174. doi: 10.1159/00035458.
[22] Ronald JA, Katzenberg R, Nielsen CH, Jae HJ, Hofmann LV, Gambhir SS. MicroRNA-regulated non-viral vectors with improved tumor specificity in an orthotopic rat model of hepatocellular carcinoma. Gene Ther 2013;20:1006–1013. doi: 10.1038/gt.2013.24.
[23] Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013;58:158–170. doi: 10.1002/hep.26305.
[24] Chen L, Zheng J, Zhang Y, Wang J, Ni J. et al. Target-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther 2011;19: 1521–1528. doi: 10.1038/mt.2011.64.
[44] Dong ZZ, Yao M, Wang L, Wu W, Gu X, Yao DF. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem 2013;13:1295–1304. doi: 10.2174/1389557513113090004

[45] Sun X, He Y, Huang C, Ma TT, Li J. Distinctive microRNA signature associated of neoplasms with the Wnt/b-catenin signaling pathway. Cell Signal 2013;25:2805–2811. doi: 10.1016/j.cellsig.2013.09.006.

[46] Dong Z, Yao M, Zhang H, Wang L, Huang H, Yan M, et al. Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis. Oncol Lett 2014;7:28–34. doi: 10.3892/ol.2013.1663.

[47] Yin X, Li YW, Jin JJ, Zhou Y, Ren ZG, Qiu SJ, et al. The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma. Oncol Lett 2013;5:1155–1162. doi: 10.3892/ol.2013.1151.

[48] Fang Y, Feng Y, Wu T, Srinivas S, Yang W, Fan J, et al. Aflatoxin B1 negatively regulates Wnt/b-catenin signaling pathway through activating miR-33a. PLoS One 2013;8:e73004. doi: 10.1371/journal.pone.0073004.

[49] King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal 2012;24:846–851. doi: 10.1016/j.cellsig.2011.12.009.

[50] Yan XD, Yao M, Wang L, Zhang HJ, Yan MJ, Gu X, et al. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation. World J Gastroenterol 2013;19:6084–6092. doi: 10.3748/wjg.v19.i36.6084.

[51] Dong ZZ, Yao M, Wang L, Yan X, Gu X, Shi Y, et al. Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. Tumor Biol 2013;34:3397–3405. doi: 10.1007/s13277-013-0912-y.

[52] Yao NH, Yao DF, Wang L, Dong Z, Wu W, Qiu L, et al. Specific miRNA inhibited IGF-II activation on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumor Biol 2012;33:1767–1776. doi: 10.1007/s13277-012-0436-x.

[53] Wu W, Yao DF, Wang YL, Qiu L, Sai W, Yang J, et al. Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumor Biol 2010;31:605–611. doi: 10.1007/s13277-010-0076-y.

[54] Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, et al. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One 2013;8:e73312. doi: 10.1371/journal.pone.0073312.

[55] Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sherr L, et al. Reciprocal regulation by TLR4 and TGF-b in tumor-initiating stem-like cells. J Clin Invest 2013;123:2832–2849. doi: 10.1172/JCI65859.

[56] Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-a/S- fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103:1617–1626. doi: 10.1038/sj.bjc.6605958.

[57] Lu Z, Zhang C, Cui J, Song Q, Wang L, Kang J, et al. Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma. Oncol Rep 2014;31:557–564. doi: 10.3892/or.2013.2877.

[58] Shen J, Wang S, Zhang YJ, Kappil MA, Chen Wu H, Kibriya MG, et al. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics 2012;7:1230–1237. doi: 10.4161/epi.22140.

[59] Saito Y, Hibi S, Saito H. Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Res 2014;44:31–44. doi: 10.1111/hepr.12147.